Fibrillation properties of human α1-acid glycoprotein

被引:14
|
作者
Scire, Andrea [1 ]
Baldassarre, Maurizio [1 ]
Galeazzi, Roberta [1 ]
Tanfani, Fabio [1 ]
机构
[1] Univ Politecn Marche, Dipartimento Sci Vita & Ambiente, I-60131 Ancona, Italy
关键词
alpha(1)-Acid glycoprotein; Orosomucoid; Protein aggregation; Amyloid-like fibrils; Nanostructures; BOVINE SERUM-ALBUMIN; FORMATION IN-VITRO; ALPHA-1-ACID GLYCOPROTEIN; AMYLOID FIBRILS; AGGREGATION; PROTEIN; MECHANISM; BINDING; TRANSTHYRETIN; OLIGOMERS;
D O I
10.1016/j.biochi.2012.09.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human alpha(1)-acid glycoprotein (AGP) is a positive acute phase plasma protein containing two disulfide bridges. Structural studies have shown that under specific conditions AGP undergoes aggregation. In this study, we analysed the nature of AGP's aggregates formed under reducing and non-reducing conditions at pH 5.5 and at relatively low temperatures. Thioflavin T and Congo red spectroscopic analyses indicated the presence of cross-beta structures in both unreduced and reduced AGP aggregates. In these samples amyloid-like fibrils were detected by transmission electron microscopy. The fibrils are branched and bent and present in very large amount in reduced AGP. Kinetics of AGP fibrillation proceeds without a lag phase and the rate constants of cross-beta formation are linearly dependent on AGP concentration and result higher under reducing conditions. The data suggest a possible downhill mechanism of polymerization with a first-order monomer concentration dependence. Bioinformatics tools highlighted an extended region that sheathes one side of the molecule containing aggregation-prone regions. Reducing conditions make the extended region less constricted, allowing greater exposure of aggregation-prone regions, thus explaining the higher propensity of AGP to aggregate and fibrillate. (c) 2012 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:158 / 166
页数:9
相关论文
共 50 条
  • [11] Binding of Lopinavir to Human α1-Acid Glycoprotein and Serum Albumin
    Gulati, Abhishek
    Boudinot, F. Douglas
    Gerk, Phillip M.
    DRUG METABOLISM AND DISPOSITION, 2009, 37 (08) : 1572 - 1575
  • [12] Characterization of binding mode of imatinib to human α1-acid glycoprotein
    Fitos, I.
    Simon, A.
    Zsila, F.
    Mady, G.
    Bencsura, A.
    Varga, Z.
    Orfi, L.
    Keri, G.
    Visy, J.
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2012, 50 (03) : 788 - 795
  • [13] Into the Labyrinth of the Lipocalin α1-Acid Glycoprotein
    Ruiz, Mario
    FRONTIERS IN PHYSIOLOGY, 2021, 12
  • [14] α1-acid glycoprotein and multidrug resistance
    Woodcock, BG
    Keese, A
    Harder, S
    Ganser, A
    Abdel-Rahman, MS
    Rietbrock, S
    DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA II, 1997, 3 : 435 - 442
  • [15] Binding of imatinib by α1-acid glycoprotein
    Gambacorti-Passerini, C
    le Coutre, P
    Zucchetti, M
    D'Incalci, M
    BLOOD, 2002, 100 (01) : 367 - 368
  • [16] Selective binding of tamsulosin to genetic variants of human α1-acid glycoprotein
    Hanada, Kazuhiko
    Tochikura, Naohiro
    Ogata, Hiroyasu
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2007, 30 (08) : 1593 - 1595
  • [17] Interaction of daunomycin antibiotic with human α1-acid glycoprotein:: Spectroscopy and modeling
    Tang, Kai
    Hu, Xing
    Zhang, Yuying
    Zou, Guolin
    JOURNAL OF MOLECULAR STRUCTURE, 2006, 788 (1-3) : 30 - 35
  • [18] Effects of Desialylation on Human α1-Acid Glycoprotein-Ligand Interactions
    Huang, Richard Y-C
    Hudgens, Jeffrey W.
    BIOCHEMISTRY, 2013, 52 (40) : 7127 - 7136
  • [19] Influence of ligand binding on structure and thermostability of human α1-acid glycoprotein
    Kopecky, Vladimir, Jr.
    Ettrich, Ruediger
    Pazderka, Tomas
    Hofbauerova, Katerina
    Reha, David
    Baumruk, Vladimir
    JOURNAL OF MOLECULAR RECOGNITION, 2016, 29 (02) : 70 - 79
  • [20] Ligand binding selectivity on genetic variants of human α1-acid glycoprotein
    Ueno, M
    Fukunaga, N
    Nishi, K
    Otagiri, M
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2005, 125 : 88 - 89